Efficacy but side effects of anakinra therapy for chronic refractory gout in a renal transplant recipient with preterminal chronic renal failure

Joint Bone Spine

Volumn 79, Issue 6, 2012, Pages 631-

  Direz, Guillaume ^a   Noël, Natacha ^a   Guyot, Charlotte ^a   Toupance, Olivier ^a   Salmon, Jean Hugues ^a   Eschard, Jean Paul ^a  

^a REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TACROLIMUS;

AGED; ANAMNESIS; CASE REPORT; CHRONIC KIDNEY FAILURE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GOUT; GRAFT RECIPIENT; HEMODIALYSIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; KNEE; LETTER; NEUTROPENIA; NEUTROPHIL COUNT; SYNOVIAL FLUID;

AGED; ANTIRHEUMATIC AGENTS; CHRONIC DISEASE; FEMALE; GOUT; GRAFT REJECTION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; NEUTROPENIA; RECEPTORS, INTERLEUKIN-1; TREATMENT OUTCOME;

EID: 84870717176     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.04.009     Document Type: Letter

References (7)

1. Richette P., Ottaviani S., Bardin T. New therapeutic options for gout. Presse Med 2011, 40:844-849. [In French].
2. So A., De Smedt T., Revaz S., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.
3. Gratton S.B., Scalapino K.J., Fye K.H. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum 2009, 61:1268-1270.
4. Sadeghi M., Daniel V., Naujokat C., et al. Decreasing plasma soluble IL-1 receptor antagonist and increasing monocyte activation early post-transplant may be involved in pathogenesis of delayed graft function in renal transplant recipients. Clin Transplant 2010, 24:415-423.
5. Manchanda P.K., Bid H.K., Kumar A., et al. Genetic association of interleukin-1beta and receptor antagonist (IL-1Ra) gene polymorphism with allograft function in renal transplant patients. Transpl Immunol 2006, 15:289-296.
6. Schiff M.H., DiVittorio G., Tesser J., et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum 2004, 50:1752-1760.
7. Yang B.B., Baughman S., Sullivan J.T. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003, 74:85-94.